Breaking Wall Street Market News & Reports

Maxygen Inc. (NASDAQ: MAXY) said Monday its CEO and chief financial officer will leave the company on Wednesday, in keeping with a collaboration with Astellas Pharma Inc, according to Associated Press.Wall Street Grand is a leading online financial publication. We are pleased to alert investors of stocks that are on the move.Sign Up for our Free Stock NewsletterJames Sulat, a member of Maxygen’s board of directors, will replace both CEO Russell Howard and CFO Larry Briscoe starting Oct. 1. Howard and Briscoe will enter consulting agreements with Maxygen.On June 30, Maxygen and Astellas expanded a partnership by forming a joint venture to identify, research, and develop Maxygen’s protein-based drug candidates for autoimmune diseases and transplant rejection. Maxygen contributed most of its drug candidates to the joint venture and will own 83 percent of it.Maxygen is transferring most of its research and development operations to the joint venture, and it said Howard, Briscoe, and Chief Operating Officer and

Johnson & Johnson (NYSE:JNJ) and Crucell, N.V., (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) recently announced that Johnson & Johnson, through its subsidiary Ortho-McNeil-Janssen Pharmaceuticals, Inc., and Crucell have entered into a strategic collaboration focusing on the discovery, development and commercialization of monoclonal antibodies and vaccines for the treatment and prevention of influenza and other infectious and non-infectious diseases. The agreement also includes 18% Equity Investment in Crucell by Johnson & Johnson and Collaboration to Develop Innovative Therapies for Other DiseasesWall Street Grand is a leading online financial publication. We are pleased to alert investors of stocks that are on the move.Sign Up for our Free Stock NewsletterThe immediate focus of the collaboration will be the development and commercialization of a universal monoclonal antibody product (flu-mAb) for the treatment and prevention of influenza. The focus of the long-term innovation collaboration will be on new

Undervalued Penny Stock Superlattice Power Inc. (OTCBB: SLAT) leads the stocks to watch on our Undervalued Penny Stocks list at Wall Street Grand. Wall Street Grand LLC, a leader in Investor Relations in the small-cap arena, is pleased to announce to the investment community and Wall Street Grand club members it’s coverage onSuperlattice Power Inc. trading on the bulletin board under the symbol OTCBB: SLAT. Superlattice Power Inc. is undervalued and has the potential for a huge breakout this morning as the rest of the investment community gets wind of SLAT. To view Wall Street Grand’s report on SLAT please visit the featured stocks section onhttp://www.wallstreetgrand.com/and don’t forget to sign up to our winning stock newsletter.Superlattice Power Inc. engages in developing rechargeable lithium ion batteries for power production in the United States. Lithium ion batteries are rechargeable and composed of cathode, anode, separator, and electrolytes.It develops rechargeable battery system for various

Small Cap Penny Stock to Watch Heartland Inc. (OTCBB: HTLJ) leads the stocks to watch on our Small Cap Penny stocks list at Wall Street Grand. Wall Street Grand LLC, a leader in Investor Relations in the small-cap arena, is pleased to announce to the investment community and Wall Street Grand club members that our coverage on Heartland Inc. – OTCBB:HTLJhas been another winning pick and still has the potential to breakout in the near future. To view Wall Street Grand’s report on HTLJ please visit the featured stocks section onwww.WallStreetGrand.comand don’t forget to sign up to our winning stock newsletter.In a recent press release Gerard Adams, President of Wall Street Grand LLC, stated “HTLJ could be one of the most undervalued companies in the small-cap arena that I have ever come across.”Gerard Adams went on to say,“Not only are the company’s revenues skyrocketing but the company is already profitable. The best part is -HTLJcurrently has market cap of only $14.3 Million. On top of this, HTLJ has deals

All State Insurance Company (NYSE:ALL) recently announced it has been named to the Carbon Disclosure Project’s (CDP) 2009 Carbon Disclosure Leadership Index, a list of the top companies demonstrating industry leading climate change disclosure practices.Wall Street Grand is a leading online financial publication. We are pleased to alert investors of stocks that are on the move.Sign Up for our Free Stock NewsletterThe index is a key component of CDP’s annual S&P 500 report with high scores indicating good internal data management and understanding of climate change related issues affecting the company. Compiled by PricewaterhouseCoopers on behalf of CDP, the 2009 Carbon Disclosure Leadership Index is intended to provide an evaluation tool for institutional investors. It comprises the top scoring 50 companies of the S&P 500 based on analysis of the responses to CDP’s 2009 Questionnaire, which focused on greenhouse gas emissions, emissions reduction targets and risks and opportunities associated with climate

Burberry Group plc (LON: BRBY) expands fashion articles adding $600 trench coats and $150 Wellington boots to entice U.S. stores into giving more space to the brand. Burberry Group is also working towards reversing falling sales in the U.S. economy.Wall Street Grand is a leading online financial publication. We are pleased to alert investors of stocks that are on the move.Sign Up for our Free Stock NewsletterThe company’s new packable coats sell for about six times less than their $3,750 lambskin suede version. Burberry plans on expanding their trench coat range, looking to reach a wider market. Last year about 7% of Burberry’s total sales came from U.S. Wholesaling. Customers of Burberry’s include Nordstrom Inc., Neiman Marcus Group Inc., Saks Inc. and Macy’s Inc.’s Bloomingdales.About Burberry Group plcBurberry Group plc is a holding company. It designs, sources, manufactures and distributes luxury men’s, women’s and children’s clothing and non-apparel accessories globally through its own retail stores,

Cardiome Pharma Corp. (NASDAQ: CRME) (TSX: COM) announced that it will extend the term of its modified “Dutch Auction” tender offer (the “Offer”) for up to US$27.5 million of its common shares commenced on September 1, 2009. The Offer, which was initially schedule to expire at 5:00 p.m. (Eastern Time) on October 6, 2009, has been extended until 5:00 p.m. (Eastern time) on October 13, 2009, unless further extended or withdrawn by the Company.Wall Street Grand is a leading online financial publication. We are pleased to alert investors of stocks that are on the move.Sign Up for our Free Stock NewsletterCardiome is extending the Offer in order to amend the offer to purchase and issuer bid circular (as amended, the “Offer to Purchase and Circular”) in order to include information about its development strategy for GED-aPC and the related transition of Dr. Charles Fisher, Chief Medical Officer and Executive Vice President, Clinical Regulatory Affairs, to a consulting role. A separate press release regarding the

Endeavour Silver Corp. (NYSE Amex:EXK) announces that it has filed amended management’s discussion and analysis for the year ended December 31, 2008 (“Amended 2008 MD&A”) and for the six months ended June 30, 2009 (“Amended 2009 Q2 MD&A”) as a result of the review of its continuous disclosure documents in connection with its proposed short form prospectus offering announced on September 17, 2009.Wall Street Grand is a leading online financial publication. We are pleased to alert investors of stocks that are on the move.Sign Up for our Free Stock NewsletterThe Amended 2008 MD&A corrects a reference to “earnings” under “Operating Performance-2008 Highlights” that should have been to “cash flow” and corrects typographical and clerical errors in cross-referencing information from the related financial statements. The Amended 2009 Q2 MD&A includes an update on use of proceeds disclosures contained in the Company’s prospectus dated February 20, 2009 in connection with a $3 million special warrants financing

Hovnanian Enterprises, Inc. (NYSE: HOV), a leading national homebuilder, recently announced that Kevork S. Hovnanian, founder and Chairman of the Board, passed away at New York Presbyterian Hospital. Mr. Hovnanian founded the Company in 1959. He led the Company as President until 1988 and as Chief Executive Officer until 1997, when his son, Ara, succeeded him as President and Chief Executive Officer. Mr. Hovnanian continued to serve as Chairman of the Board. He was 86 years old.Wall Street Grand is a leading online financial publication. We are pleased to alert investors of stocks that are on the move.Sign Up for our Free Stock Newsletter”Mr. Hovnanian was the heart and soul of our Company and all of our associates mourn this tragic loss. Our deepest condolences and prayers are with Mr. Hovnanian’s wife, Sirwart, and his entire family,” stated J. Larry Sorsby, Executive Vice President and Chief Financial Officer. “Mr. Hovnanian was a visionary who brought tremendous leadership, energy and passion to his job.